Erkrankungen durch hochpathogene Erreger – Teil 2

Die Prävention hochkontagiöser Krankheiten wird durch die leichte Übertragbarkeit der Erreger erschwert. Besteht ein begründeter Verdacht, muss der Patient sofort für die Dauer der Infektiosität isoliert werden. Die weitere Behandlung erfolgt in einem der 7 deutschen Behandlungszentren mit einer Sonderisolierstation. Welche weiteren lebensbedrohlichen Infektionskrankheiten auch in Europa relevant sind und was bei der hochspezialisierten Versorgung dieser Patienten zu beachten ist, lesen Sie im 2. Teil.

Schlüsselwörter

Hochpathogene Erreger - Ebolafieber - Lassafieber - Milzbrand - Lungenpest - Tierpocken - Sonderisolierstation - STAKOB - Schutzausrüstung

• Literatur

• 1 Abdelrahman Z, Li M, Wang X. Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses. Front Immunol 2020; 11: 552909
• 2 World Health Organization (WHO). MERS situation update – February 2022. Accessed September 09, 2022 at: https://applications.emro.who.int/docs/WHOEMCSR502E-eng.pdf?ua=1
• 3 de Wit E, Doremalen N van, Falzarano D. et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016; 14: 523-534
• 4 Zaki AM, Boheemen S van, Bestebroer TM. et al. Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. New Engl J Med 2012; 367: 1814-1820
• 5 Mostafa A, Kandeil A, Shehata M. et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): State of the Science. Microorg 2020; 8: 991
• 6 Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015; 386: 995-1007
• 7 Chowell G, Abdirizak F, Lee S. et al. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Med 2015; 13: 210
• 8 Verordnung über Sicherheit und Gesundheitsschutz bei Tätigkeiten mit Biologischen Arbeitsstoffen. Accessed September 09, 2022 at: http://www.gesetze-im-internet.de/biostoffv_2013/
• 9 Das KM, Lee EY, Enani MA. et al. CT Correlation With Outcomes in 15 Patients With Acute Middle East Respiratory Syndrome Coronavirus. Am J Roentgenol 2015; 204: 736-742
• 10 Dawson P, Malik MR, Parvez F. et al. What Have We Learned About Middle East Respiratory Syndrome Coronavirus Emergence in Humans? A Systematic Literature Review. Vector Borne Zoonotic Dis 2019; 19: 174-192
• 11 Hu B, Zeng LP, Yang XL. et al. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog 2017; 13: e1006698
• 12 Webster RG, Govorkova EA. Continuing challenges in influenza. Ann N Y Acad Sci 2017; 1323: 115-139
• 13 Steel J, Lowen AC. Influenza Pathogenesis and Control - Volume I. Curr Top Microbiol 2014; 385: 377-401
• 14 Kim H, Webster RG, Webby RJ. Influenza Virus: Dealing with a Drifting and Shifting Pathogen. Viral Immunol 2018; 31: 174-183
• 15 Taniguchi K, Ando Y, Nobori H. et al. Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Sci Rep 2019; 9: 3466
• 16 Kiso M, Yamayoshi S, Furusawa Y. et al. Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil. Viruses 2019; 11: 1066
• 17 Proença-Módena JL, Macedo IS, Arruda E. H5N1 avian influenza virus: an overview. Braz J Infect Dis 2007; 11: 125-133
• 18 World Health Organization (WHO). Cumulative number of confirmed human cases for avian influenza A (H5N1) reported to WHO, 2003–2021, 15 April 2021. Accessed September 09, 2022 at: https://www.who.int/publications/m/item/cumulative-number-of-confirmed-human-cases-for-avian-influenza-a(h5n1)-reported-to-who-2003-2021-15-april-2021
• 19 Noshi T, Kitano M, Taniguchi K. et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antivir Res 2018; 160: 109-117
• 20 Le QM, Kiso M, Someya K. et al. Isolation of drug-resistant H5N1 virus. Nature 2005; 437: 1108
• 21 Shittu I, Bianco A, Gado D. et al. First detection of highly pathogenic H5N6 avian influenza virus on the African continent. Emerg Microbes Infect 2020; 9: 886-888
• 22 Fouchier RAM, Schneeberger PM, Rozendaal FW. et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc National Acad Sci 2004; 101: 1356-1361
• 23 Lübbert C, Pietsch C. Orthopoxviren. Dtsch Med Wochenschr 2022; 147: 411-417
• 24 Duggan AT, Perdomo MF, Piombino-Mascali D. et al. 17th Century Variola Virus Reveals the Recent History of Smallpox. Curr Biol 2016; 26: 3407-3412
• 25 Nitsche A, Pauli G. Sporadic human cases of cowpox in Germany. Euro Surveill 2007; 12: E070419.3
• 26 Becker C, Kurth A, Hessler F. et al. Cowpox Virus Infection in Pet Rat Owners. Dtsch Ärzteblatt Int 2009; 106: 329-334
• 27 Wendt R, Tittelbach J, Schrick L. et al. Generalized cowpox virus infection in an immunosuppressed patient. Int J Infect Dis 2021; 106: 276-278
• 28 Russo AT, Grosenbach DW, Chinsangaram J. et al. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti-infective Ther 2020; 19: 331-344
• 29 Baker RO, Bray M, Huggins JW. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antivir Res 2003; 57: 13-23
• 30 Petersen E, Kantele A, Koopmans M. et al. Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention. Infect Dis Clin N Am 2019; 33: 1027-1043
• 31 Likos AM, Sammons SA, Olson VA. et al. A tale of two clades: monkeypox viruses. J Gen Virol 2005; 86: 2661-2672
• 32 Heymann DL, Szczeniowski M, Esteves K. Re-emergence of monkeypox in Africa: a review of the past six years. Brit Med Bull 1998; 54: 693-702
• 33 Learned LA, Reynolds MG, Wassa DW. et al. Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg 2005; 73: 428-434
• 34 Centers for Disease Control and Prevention (CDC). Multistate outbreak of monkeypox--Illinois, Indiana, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep 2003; 52: 537-540
• 35 World Health Organization (WHO). Monkeypox. Accessed September 09, 2022 at: https://www.who.int/news-room/fact-sheets/detail/monkeypox
• 36 McCollum AM, Damon IK. Human Monkeypox. Clin Infect Dis 2014; 58: 260-267
• 37 Nalca A, Zumbrun EE. ACAM2000TM: The new smallpox vaccine for United States Strategic National Stockpile. Drug Des Dev Ther 2010; 4: 71-79
• 38 Kenner J, Cameron F, Empig C. et al. LC16m8: An attenuated smallpox vaccine. Vaccine 2006; 24: 7009-7022
• 39 Brisse ME, Ly H. Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors. Front Immunol 2019; 10: 372
• 40 Cajimat MNB, Milazzo ML, Bradley RD. et al. Ocozocoautla de Espinosa Virus and Hemorrhagic Fever, Mexico. Emerg Infect Dis 2012; 18: 401-405
• 41 Gomez RM, de Giusti CJ, Vallduvi MMS. et al. Junín virus: A XXI century update. Microbes Infect 2011; 13: 303-311
• 42 Clark LE, Mahmutovic S, Raymond DD. et al. Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses. Nat Commun 2018; 9: 1884
• 43 Centers for Disease Control and Prevention (CDC). Nipah Virus (NiV). Accessed September 09, 2022 at: https://www.cdc.gov/vhf/nipah/index.html
• 44 Li J, Li S, Yang L. et al. Severe fever with thrombocytopenia syndrome virus: a highly lethal bunyavirus. Crit Rev Microbiol 2020; 47: 1-14
• 45 Stenseth NC, Atshabar BB, Begon M. et al. Plague: Past, Present, and Future. PLoS Med 2008; 5: e3
• 46 Ligon BL. Plague: A Review of its History and Potential as a Biological Weapon. Sem Ped Infect Dis 2006; 17: 161-170
• 47 Prentice MB, Rahalison L. Plague. Lancet 2007; 369: 1196-1207
• 48 Inglesby TV, Dennis DT, Henderson DA. et al. Plague as a Biological Weapon: Medical and Public Health Management. JAMA 2000; 283: 2281-2290
• 49 Oyston PC, Williamson ED. Prophylaxis and therapy of plague. Expert Rev Anti-infective Ther 2014; 11: 817-829
• 50 Titball RW, Williamson ED. Yersinia pestis (plague) vaccines. Expert Opin Biol Ther 2005; 4: 965-973
• 51 Schwartz M. Dr. Jekyll and Mr. Hyde: A short history of anthrax. Mol Aspects Med 2009; 30: 347-355
• 52 Grunow R, Verbeek L, Jacob D. et al. Injection Anthrax. Dtsch Arztebl Int 2012; 109: 843-848
• 53 Moayeri M, Leppla SH, Vrentas C. et al. Anthrax Pathogenesis. Ann Rev Microbiol 2014; 69: 1-24
• 54 Beatty ME, Ashford DA, Griffin PM. et al. Gastrointestinal Anthrax: Review of the Literature. Arch Intern Med 2003; 163: 2527-2531
• 55 Lanska DJ. Anthrax meningoencephalitis. Neurology 2002; 59: 327-334
• 56 Hendricks KA, Wright ME, Shadomy SV. et al. Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults. Emerg Infect Dis 2014; 20: e130687
• 57 Zakowska D, Bartoszcze M, Niemcewicz M. et al. Bacillus anthracis infections – new possibilities of treatment. Ann Agr Env Med 2015; 22: 202-207
• 58 Kummerfeldt CE. Raxibacumab: potential role in the treatment of inhalational anthrax. Infect Drug Resist 2014; 7: 101-109
• 59 Greig SL. Obiltoxaximab: First Global Approval. Drugs 2016; 76: 823-830
• 60 Baillie LW. Is new always better than old? The development of human vaccines for anthrax. Hum Vaccines 2009; 5: 806-816
• 61 Inglesby TV, O’Toole T, Henderson DA. et al. Anthrax as a Biological Weapon, 2002: Updated Recommendations for Management. JAMA 2002; 287: 2236-2252
• 62 Jernigan JA, Stephens DS, Ashford DA. et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7: 933-944
• 63 Robert Koch-Institut (RKI). Umgang mit an Milzbrand erkrankten Patienten im Krankenhaus und in OP-Einheiten. Accessed September 09, 2022 at: https://www.rki.de/DE/Content/InfAZ/A/Anthrax/Milzbrand_Hinweise-UmgangPatientenKrankenhaus-OP.pdf